Filippo

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

Retrieved on: 
Tuesday, July 18, 2023
University, OSI Pharmaceuticals, William Blair & Company, Cancer, Research, Saint John's University, CAR, Syracuse University, Business administration, Wedbush Securities, Patient, Wells Fargo, Growth, Master of Business Administration, Cornell University, Pharmaceutical industry, Filippo, Science

LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.

Key Points: 
  • LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.
  • Mr. Petti has also been named as a member of Leucid Bio's Board of Directors.
  • Most recently, Mr. Petti was Chief Executive Officer and Chief Financial Officer of Celyad Oncology SA, a biotechnology company focused on CAR-T cell therapies for cancer.
  • Filippo Petti, newly appointed Chief Executive Officer, added: "Leucid's unique approach to the field of CAR-T has tremendous potential to help cancer patients around the world.

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

Retrieved on: 
Tuesday, July 18, 2023
University, OSI Pharmaceuticals, William Blair & Company, Cancer, Research, Saint John's University, CAR, Syracuse University, Business administration, Wedbush Securities, Patient, Wells Fargo, Growth, Master of Business Administration, Cornell University, Pharmaceutical industry, Filippo, Science

LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.

Key Points: 
  • LONDON, July 18, 2023 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company's proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect.
  • Mr. Petti has also been named as a member of Leucid Bio's Board of Directors.
  • Most recently, Mr. Petti was Chief Executive Officer and Chief Financial Officer of Celyad Oncology SA, a biotechnology company focused on CAR-T cell therapies for cancer.
  • Filippo Petti, newly appointed Chief Executive Officer, added: "Leucid's unique approach to the field of CAR-T has tremendous potential to help cancer patients around the world.

Key linkages between banks and the non-bank financial sector

Retrieved on: 
Saturday, June 3, 2023
Filippo, Insurance, European Parliament, B.4, Contract, European, St. Louis Fed Financial Stress Index, Disclosure, Article, Finance, Common, Commodity, Archegos Capital Management, AnaCredit, Book, European Banking Authority, Time, FSR, Risk, ECB, Council, Identifying marks on euro coins, Growth, B.2, NBFI, B.3, B.1, Financial services, Cryptocurrency, Bank, Security (finance), Bookkeeping, Credit, EU
Key Points: